Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
More IPOs will likely rush to list in Hong Kong after seeing Kuaishou Technology (1024 HK)'s spectacular debut. If share priced had only doubled, valuation would be expensive but not exorbitant. But with the 161% gain on first day, share price could use a little breather. But momentum may not let up since there are expectations of passive flows buying in the near term.
We are already expecting a handful of Hong Kong secondary listings and this week, there were news reports that Tencent Music (TME US) has selected banks for the listing, which could raise as much as US$5bn. There was also reports that said Naiyuki (Naixue Tea) is looking to list in Hong Kong with a US$500m deal size, a change from its initial US IPO plans.
IPO bookbuild launch this week include New Horizon Health (NHH HK) while we are hearing that Sciclone Pharmaceuticals, Inc (SCLN US) is premarketing after getting its approval from HKEX.
In India, Indigo Paints (INDIGOPN IN) and Home First Finance (HFF IN) traded well as expected while Brookfield India Real Estate Trust (BIREIT IN) closed its IPO bookbuild with 8x oversubscription rate. We covered the IPO last week:
Further away from home, in the US, Cloopen Group Holding Ltd (RAAS US) launched its IPO on Thursday and was already looking to close books early (a day later) citing strong demand. We shared out thoughts on the company as well as trade idea via Hi Sun Technology China (818 HK).
Last but not least, Thai Beverage (THBEV SP)'s beer unit is looking to premarket as early as March while Aztech (AZ SP) has already started pre-marketing its US$225m IPO and it is looking to launch in early March.
Placements this week:
Our overall accuracy rate is 73.9% for IPOs and 67.3% for Placements
(Performance measurement criteria is explained at the end of the note)
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.